Accessibility Menu
Avaí Bio logo

Avaí Bio(OTC) AVAI

Market Cap$20.35MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-74%
5 Year-96%
1 Year-64%
1 Month-29%
$0.13
+12.51%
+0.01Today
Avaí Bio last closing stock price
MetricPriceDate
Last closeUSD 0.132026-08-21
Avaí Bio stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+5.76%USD 0.132026-08-14
1 month-28.54%USD 0.192026-07-22
3 month-44.27%USD 0.242026-05-22
Year to date-65.21%USD 0.382025-12-31
1 year-64.27%USD 0.372025-08-21
3 year-89.42%USD 1.252023-08-22
5 year-95.86%USD 3.192021-08-20
Since inception-73.56%USD 0.502020-04-06

Avaí Bio Financials at a Glance

Market Cap

$20.35MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$1.81M

EPS (TTM)

-$0.01

P/E Ratio

-10.41

Dividend

$0.00

Beta (Volatility)

0.33 (Low)

Price

$0.13

Volume

1,100

Open

$0.12

Previous Close

$0.13

Daily Range

$0.12 - $0.13

52-Week Range

$0.11 - $0.80

Estimated Earnings Date

N/A

AVAI News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Avaí Bio

Avant Technologies builds artificial intelligence tools and news apps for businesses and consumers. Its software helps users process information and manage digital assets more efficiently. The company also offers consulting to help organizations manage technology projects and data.

Products and Services

  • AI Software: Proprietary artificial intelligence models for text generation and data analysis (0% of revenue).
  • Digital Asset Tools: InstantFAME platform for digital ratings and secure sales of digital works (0% of revenue).
  • Healthcare AI: Vision AI, developed through a joint venture, detects diseases from retinal scans (0% of revenue).
  • News Aggregation: Thy News app collects news from over 149,000 sources for customizable feeds (0% of revenue).
  • IT Consulting: Services include project management, software administration, and asset management for businesses (0% of revenue).

Growth and Expansion

  • Acquired Avant! AI and InstantFAME assets in April 2023 to expand technology offerings.
  • Formed a joint venture with Ainnova Tech in November 2024 for healthcare AI in the US, Canada, and Europe.
  • Signed a letter of intent in June 2024 to buy up to 50 supercomputer servers from Flow Wave, pending a $20 million capital raise.
  • Attempted to acquire technology assets from Wired4Health in April 2024, but canceled the deal in September 2024.

What Makes Avant Technologies Stand Out

Avant Technologies focuses on proprietary AI that learns from unlabeled data, making it adaptable across industries. Its single-segment structure allows for streamlined management and resource allocation. The company’s joint ventures target both business and healthcare applications, broadening its potential reach.

Five Things You Need to Know

  • No revenue reported for Q2 2025 or prior two years.
  • Net loss was $487,589 in Q2 2025, improving 8% from Q2 2024.
  • Operating expenses fell 6% to $487,589 in Q2 2025.
  • Cash used in operations was $240,343 in Q2 2025, up from Q2 2024.
  • Working capital deficit reached $2,116,555 as of June 30, 2025.

Bottom Line

Avant Technologies has shifted from acquisitions to developing proprietary AI and digital tools. The company remains in early stages, with no revenue and ongoing funding needs.

AI Generated • Apr 16, 2026

Industry

IT Services

Sector

Information Technology

Employees

2

CEO

Martin Chris Winter

Website

www.avanttechnologies.com

Headquarters

Vilnius, NV 89108, LT

AVAI Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

65.17%

Return on Capital

N/A

Return on Assets

-229.11%

Earnings Yield

-9.61%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$20.35MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

153.92M

Volume

1.10K

Avg. Volume

141.35K

Financials (TTM)

Gross Profit

-$24.80K

Operating Income

-$1.42M

EBITDA

-$1.45M

Operating Cash Flow

-$1.18M

Capital Expenditure

-$6.00

Free Cash Flow

-$1.18M

Cash & ST Invst.

$83.59K

Total Debt

$2.28M

Avaí Bio Performance Analysis

Avaí Bio annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-03-31USD 276,324-70.0%
20242024-03-31USD 0N/A
20252025-03-31USD 0N/A
20262026-03-31USD 0N/A
Avaí Bio sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-09-30N/A
Q32025-12-31N/A
Q42026-03-31N/A
Q12026-06-30N/A
Avaí Bio annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-03-31USD -0.0189.6%
20242024-03-31USD -0.02170.3%
20252025-03-31USD -0.01-63.8%
20262026-03-31USD -0.0142.7%
Avaí Bio sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-09-305.7%
Q32025-12-31-21.2%
Q42026-03-3155.0%
Q12026-06-30-100.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$5.24K

+19.5%

Gross Margin

0.00%

N/A

Market Cap

$20.35MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$20.35M

N/A

Employees

1

N/A

Net Income

-$552.04K

-13.2%

EBITDA

-$414.54K

+13.8%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$83.59K

+730.7%

Total Debt

$2.28M

+125.6%

Accounts Receivable

$60.10K

N/A

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$2.28M

+125.6%

Return on Assets

-2.29%

N/A

Return on Invested Capital

44.10%

N/A

Free Cash Flow

-$414.26K

-72.4%

Operating Cash Flow

-$414.26K

-72.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
NYWKFNTG Clarity Networks Inc.
$0.57+1.24%
INVUInvestview, Inc.
$0.02-8.93%
FCGYForecastagility Corporation
$0.00+0.00%
MHUBFMinehub Technologies Inc.
$0.41+1.84%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.77+0.10%
IBITiShares Bitcoin Trust
$43.68+0.06%
BITOProShares Trust - ProShares Bitcoin ETF
$10.41+0.06%
MARAMara Holdings
$11.26+0.01%

Questions About AVAI

What is the current price of Avaí Bio?

Avaí Bio is trading at $0.13 per share.

What is the 52-week range for Avaí Bio?

Over the past 52 weeks, Avaí Bio has traded between $0.11 and $0.80.

How much debt does Avaí Bio have?

As of the most recent reporting period, Avaí Bio reported total debt of $2.28M.

How much cash does Avaí Bio have on hand?

Avaí Bio reported $83.59K in cash and cash equivalents in its most recent financial results.

What is Avaí Bio’s dividend yield?

Avaí Bio does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services